Considering the widespread use of the cell line, these findings could have significant implications for the research community.
The test will identify NSCLC patients with PD-L1 expression who are likely to benefit from Merck's Keytruda, which has received a positive opinion from European regulators.
The deal marks the first software-related acquisition for Agilent since the firm acquired Cartagenia last year.
While most firms launched new mass spec systems, the larger focus was on developing and implementing the larger workflows surrounding these instruments.
The company currently offers target amplification assays for diagnostic use and clinical research that are based on a proprietary multiplex PCR technology.
Qiagen has extended the offer period for its DKK683 million ($103.5 million) acquisition of Exiqon.
The firms plan to combine Sophia's DDM software with Multiplicom's molecular diagnostic kits, and sell the solution to European hospitals and laboratories.
Agilent recorded Q2 revenues of $ 1.02 billion compared to $963 million in Q2 2015, beating the average Wall Street estimate of $983.3 million.
Exome sequences and copy number patterns suggest lung adenocarcinoma and squamous cell carcinoma are each marked by specific somatic mutations and driver genes.
Agilent will provide technology and training for the jointly-run lab, expanding on a 2011 deal to open a microarray technology center at Monash University Malaysia.
The US Department of Justice has proposed a rule change to enable DNA to be collected from migrants, the Associated Press reports.
Bernard Fisher, a surgeon who changed how breast cancer is treated, has died at 101, the New York Times reports.
A Washington Post columnist writes that she is skeptical about DNA-based diets.
In PNAS this week: recurrent inactivation of DEPDC5 in gastrointestinal stromal tumors, taxonomic reliability of GenBank sequences, and more.